This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
Information provided by:
Repligen Corporation Identifier:
First received: May 7, 2003
Last updated: August 4, 2005
Last verified: August 2005
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Condition Intervention Phase
Mitochondrial Diseases Drug: RG2133 (2',3',5'-tri-O-acetyluridine) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Resource links provided by NLM:

Further study details as provided by Repligen Corporation:

Estimated Enrollment: 12

Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Mitochondrial Disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information Identifier: NCT00060515     History of Changes
Other Study ID Numbers: RG2133-01
Study First Received: May 7, 2003
Last Updated: August 4, 2005

Additional relevant MeSH terms:
Mitochondrial Diseases
Metabolic Diseases processed this record on September 19, 2017